TB-500 must be matched to the actual research substance. The cited FDA review identifies N-acetyl-LKKTETQ, a fragment rather than full-length thymosin beta-4. Evidence should not be transferred automatically between them.
How do fragment and full-length peptide differ?
The 2026 scientific review distinguishes the seven-residue TB-500 fragment from 43-residue thymosin beta-4. Sequence overlap does not make their evidence interchangeable. Reference: FDA — TB-500 scientific review (2026)
How should repair claims be read?
Identify the molecule, the experimental setting and the outcome. Cells, animals and clinical function answer different questions; a proposed mechanism is not proof of tendon treatment in people.
Does a label name identify all relevant evidence?
An abbreviation alone cannot match a product to a study. Composition and formulation matter. An agency meeting document also is not an efficacy approval for every product bearing the name.
Frequently asked questions
Can TB-500 and thymosin beta-4 be used interchangeably in articles?
No. Specify whether the fragment or full-length molecule was studied.
Does this FDA review prove injury-treatment efficacy?
No. Substance review and demonstrated clinical benefit are separate steps.
How should this article be used?
Use it to identify the substance, understand what the cited research measured, and prepare questions for a qualified clinician. It is educational information, not an individual treatment plan.